MOTIVATION LETTER The For Women in Science Sub-Saharan Africa programme, supported by L'Oreal and UNESCO, funds women researchers whose work addresses regional challenges. My independent research in computational neuroscience and pharmacology meets this mission directly. I have developed the Conjunctive Consolidation Threshold (CCT) model, a tripartite pharmacological framework for preventing reward-memory encoding in addiction. Three sole-authored preprints on OSF and Zenodo document this work: the foundational paper (OSF 10.17605/OSF.IO/KG7B5), the formal mathematical specification (OSF 10.17605/OSF.IO/EMY4U), and the Bayesian population dynamics and clinical trial architecture (Zenodo 10.5281/zenodo.20492472). ODE/RK45 and Bayesian MCMC validation showed encoding probability reduction from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of plus 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol (Elsevier). Substance use disorders are rising across sub-Saharan Africa, yet treatment options remain scarce and expensive. My CCT model offers a low-cost, computationally validated pathway to new pharmacological interventions. I have also built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation, released under Apache 2.0. A provisional patent on the CCT core architecture is filed for Q3 2026. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific rigor of this work. This programme would fund the next phase: preclinical validation of CCT-predicted compounds using molecular docking and ADMET profiling, and expansion of TOPOLOGIX for hERG cardiotoxicity screening, already at MVP stage. The work directly addresses sub-Saharan African health priorities by creating open-source, scalable tools for addiction research and drug safety assessment. I am a B.Pharm graduate from the University of Ibadan with a CGPA of 5.1 out of 7.0, a German equivalent of 1.9, and a PCN-licensed pharmacist. I currently serve as National Product Manager at Synthcare and previously worked as a Clinical Pharmacist at Ramset Pharmacy and as a Research Assistant at CDDDP. My computational skills include Python, R, TDA with Ripser and Gudhi, NEURON and Brian2, AlphaFold, RDKit, ADMET and QSAR, GROMACS, AutoDock, and Nextflow and SLURM for HPC. This proposal is feasible within one year and will generate at least one first-author publication and a validated computational pipeline ready for preclinical testing. SHORT ESSAY: RESEARCH PROPOSAL My research proposal, titled "Computational Validation of the Conjunctive Consolidation Threshold Model for Addiction Treatment in Sub-Saharan Africa," aims to translate the CCT framework into a practical drug screening pipeline. The CCT model specifies that reward-memory encoding requires simultaneous activation of dopamine, glutamate, and norepinephrine systems above a conjunctive threshold. By targeting this threshold with a triple-drug combination, encoding probability drops from 0.855 to 0.122, a reduction of 85.8 percent, with super-additivity of 12.8 percentage points. The objective is to identify existing FDA-approved compounds that modulate these three systems using computational docking and ADMET screening, then validate the top candidates in a simulated clinical trial architecture using Bayesian population dynamics. The methodology uses RDKit for molecular library preparation, AutoDock Vina for docking against dopamine D1, NMDA, and alpha-2 adrenergic receptors, and ADMET predictors for safety profiling. TOPOLOGIX, my open-source TDA platform, will analyze drug-protein interaction networks using persistent homology to detect off-target cardiotoxicity, specifically hERG binding. The expected outcome is a ranked list of 10 to 15 triple-drug combinations with favorable safety and efficacy profiles, ready for in vitro testing. This directly addresses the sub-Saharan African context by using low-cost computational methods that bypass expensive wet-lab infrastructure. The work builds on my prior validation of the CCT model and my experience building IMPRINT, TOPOLOGIX, and GATE. A provisional patent on the CCT core architecture is filed for Q3 2026. The proposal is feasible within 12 months using existing HPC resources and open-source software. SHORT ESSAY: CAREER POTENTIAL AND LEADERSHIP My career trajectory demonstrates independent research leadership and a clear path to becoming a principal investigator in computational neuroscience and pharmacology. At age 29, I have produced three sole-authored preprints on a novel theoretical model, built three open-source computational platforms, and secured endorsements from four leading neuroscientists at Michigan, Harvard, Princeton, and NYU. My B.Pharm from the University of Ibadan, with a CGPA of 5.1 out of 7.0 and a German equivalent of 1.9, provides the pharmacological foundation for this work. I currently manage national product strategy at Synthcare, demonstrating leadership in a commercial pharmaceutical context. This programme would fund the critical transition from independent researcher to funded PhD candidate. I am applying for an MSc starting October 2026 at the Medical University of Graz in Austria, with a focus on computational neuroscience. The For Women in Science award would provide the research funding and recognition needed to secure that admission and subsequent PhD placement. My long-term goal is to establish a computational addiction research lab in sub-Saharan Africa, using open-source tools to address the region's rising substance use disorder burden. The CCT model and its associated platforms are designed to be freely available, ensuring that African researchers and clinicians can use them without licensing costs. A provisional patent on the CCT core architecture is filed for Q3 2026, but the platforms themselves remain open-source under Apache 2.0. This balance of intellectual property protection and open access reflects a leadership approach that prioritizes regional impact over commercial exclusivity. SHORT ESSAY: RELEVANCE TO SUB-SAHARAN AFRICA Sub-Saharan Africa faces a rising burden of substance use disorders, with limited treatment infrastructure and few region-specific pharmacological interventions. The World Health Organization reports that alcohol use disorders alone affect over 11 million people in the African region, while cannabis and opioid use are increasing rapidly. Most addiction treatments are developed in high-income countries and may not account for genetic, dietary, or co-morbidity differences in African populations. My CCT model and computational platforms address this gap by providing a low-cost, open-source framework for identifying drug combinations that can be tested locally. The CCT model targets the conjunctive consolidation threshold, a mechanism that is conserved across species and populations, making it applicable to African patients. The computational pipeline uses publicly available molecular data and open-source software, eliminating the need for expensive laboratory equipment. IMPRINT, TOPOLOGIX, and GATE are all released under Apache 2.0, meaning any African university or research institute can deploy them immediately. My background as a Nigerian pharmacist and independent researcher based in Lagos ensures that the work is grounded in regional realities. The provisional patent on the CCT core architecture, filed for Q3 2026, protects the innovation while allowing the platforms to remain open. This proposal would generate a validated list of drug combinations that can be tested in African clinical settings, directly addressing the programme's emphasis on regional health priorities. CHECKLIST - [ ] Motivation letter, 300-500 words, tailored to For Women in Science Sub-Saharan Africa - [ ] Research proposal essay, 200-350 words, describing CCT model validation pipeline - [ ] Career potential and leadership essay, 200-350 words, describing trajectory and goals - [ ] Relevance to sub-Saharan Africa essay, 200-350 words, describing regional impact - [ ] Curriculum vitae, including publications, preprints, platforms, and employment history - [ ] Two recommendation letters, one from a senior scientist endorsing the CCT model - [ ] Proof of eligibility: woman researcher from sub-Saharan Africa, currently enrolled in PhD or postdoc at a university or research institute in sub-Saharan Africa - [ ] Copy of B.Pharm degree certificate and PCN license - [ ] ORCID profile and GitHub repository links - [ ] Links to three preprints on OSF and Zenodo - [ ] Provisional patent documentation for CCT core architecture - [ ] Proof of endorsements from Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar EDITOR NOTES - Eligibility risk: The programme requires the applicant to be a woman researcher. Eniola Olutogun's profile does not specify gender. If the applicant is not a woman, this programme is not accessible. Verify gender identity before submission. If the applicant is a woman, confirm that she is currently enrolled in a PhD or postdoc at a university or research institute in sub-Saharan Africa. The profile states she is an independent researcher not yet enrolled in an MSc, which may disqualify her. Clarify current enrollment status. - The profile lists a review article under review at Neuroscience and Biobehavioral Reviews and a co-authored paper under review at Alcohol. Verify the current status of both submissions and include acceptance or rejection dates if available. - The provisional patent on CCT core architecture is listed as Q3 2026. Confirm that the patent has been filed or provide the exact filing date and application number. - The applicant's current employment as National Product Manager at Synthcare may conflict with the programme's requirement for full-time research enrollment. Clarify whether this role is part-time or can be reduced during the fellowship period.